The latest combination therapy to receive regulatory approval (TrikaftaTM (elexacaftor-tezacaftor-ivacaftor)) promises to benefit ~90% of CF subjects, including individuals homozygous for F508del-CFTR and those with F508del-CFTR and a minimal-function mutation [2,3]. Here, CFTR is linked to cystic fibrosis.